Lymph directing prodrugs
US-2024050573-A1 · Feb 15, 2024 · US
Cannabinoids in combination with non-cannabinoid chemotherapeutic agents
US2021069333A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021069333-A1 |
| Application number | US-202017102109-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 23, 2020 |
| Priority date | Jun 4, 2008 |
| Publication date | Mar 11, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
First claim
Opening claim text (preview).
1 - 20 . (canceled) 21 . A method for treating glioma in a human in need thereof, comprising: administering to the human: (i) tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and (ii) temozolomide. 22 . The method of claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5. 23 . The method of claim 21 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2. 24 . The method of claim 21 , wherein a botanical drug substance comprising the THC and CBD is administered to the human. 25 . The method of claim 21 , wherein the human has a glioma tumour. 26 . The method of claim 25 , wherein the glioma tumour is glioblastoma multiforme (GBM). 27 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered separately. 28 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered sequentially. 29 . The method of claim 21 , wherein the THC and CBD, and the temozolomide are administered simultaneously. 30 . A method for increasing the efficacy of temozolomide in inhibiting cancer cell growth or reducing cancer cell viability comprising: administering to a human having a glioma tumour: (i) a botanical drug substance comprising tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:20; and (ii) temozolomide. 31 . The method of claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:5. 32 . The method of claim 30 , wherein the THC and CBD are in a ratio based on weight between 1:1 and 1:2. 33 . The method of claim 30 , wherein the glioma tumour is a glioblastoma multiforme (GBM). 34 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered separately. 35 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered sequentially. 36 . The method of claim 30 , wherein the THC and CBD, and the temozolomide are administered simultaneously.
Assignees
Inventors
Classifications
o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title
Antineoplastic agents · CPC title
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title
- A61K31/138Primary
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
Platinum compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021069333A1 cover?
- The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherape…
- Who is the assignee on this patent?
- Gw Pharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/138. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Mar 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).